• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » UK Sets Three New Post-Brexit Policies for Clinical Trials

UK Sets Three New Post-Brexit Policies for Clinical Trials

January 11, 2021

In its ongoing effort to replace EU clinical trial policies with UK-specific guidance, the Medicines and Healthcare products Regulatory Agency (MHRA) has issued three clinical trial guidances on registering and publishing results of trials, submitting safety reports and making substantial changes to trial applications.

Trials conducted in the UK should register with and report results to one of the international trial databases, according to the first guidance, such as ClinicalTrials.gov in the U.S. or the International Standard Randomized Controlled Trial Number (ISRCTN) registry recognized by the World Health Organization. Trials with sites in both the UK and the EU can use the EU Clinical Trials Register.

The second guidance directs trials to submit Suspected Unexpected Serious Adverse Reaction (SUSAR) reports through the MHRA gateway, the eSUSAR website or MHRA’s Individual Safety Case Reports submission portal. For trials operating in both the UK and the EU, SUSAR reports must be submitted to MHRA, the relevant EU member state and the European Medicines Agency’s Eudravigilance Clinical Trial Module.

Sponsors that need to make substantial amendments to their trial applications, such as a change of sponsor or legal representative or addition of a license holder to the existing marketing authorization, must inform both MHRA and the UK’s Regulatory Ethics Committee, according to the third guidance.

Read the three guidances here: https://bit.ly/35nq8x8, https://bit.ly/39eKoSX and https://bit.ly/39eKpX1.

COVID-19
  • Related Directories

    Veklury (remdesivir)

    Pfizer-BioNtech COVID-19 Vaccine

    Moderna COVID-19 Vaccine (mRNA-1273)

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing